4,565 Shares in Novartis AG $NVS Bought by South Shore Capital Advisors

South Shore Capital Advisors acquired a new position in shares of Novartis AG (NYSE:NVS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,565 shares of the company’s stock, valued at approximately $629,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Fisher Asset Management LLC grew its position in Novartis by 1.7% during the 3rd quarter. Fisher Asset Management LLC now owns 7,239,366 shares of the company’s stock worth $928,376,000 after acquiring an additional 117,952 shares during the last quarter. Bank of America Corp DE lifted its holdings in Novartis by 1.7% during the 3rd quarter. Bank of America Corp DE now owns 4,605,878 shares of the company’s stock worth $590,658,000 after buying an additional 78,390 shares during the period. Northern Trust Corp lifted its holdings in Novartis by 7.7% during the 3rd quarter. Northern Trust Corp now owns 2,371,389 shares of the company’s stock worth $304,107,000 after buying an additional 168,573 shares during the period. Envestnet Asset Management Inc. lifted its holdings in Novartis by 4.7% during the 3rd quarter. Envestnet Asset Management Inc. now owns 1,819,260 shares of the company’s stock worth $233,302,000 after buying an additional 82,369 shares during the period. Finally, Raymond James Financial Inc. lifted its holdings in Novartis by 77.7% during the 3rd quarter. Raymond James Financial Inc. now owns 1,648,174 shares of the company’s stock worth $211,362,000 after buying an additional 720,860 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis Stock Down 0.7%

Shares of NYSE:NVS opened at $153.00 on Tuesday. The company has a market capitalization of $323.19 billion, a price-to-earnings ratio of 21.37, a P/E/G ratio of 2.64 and a beta of 0.52. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.12 and a quick ratio of 0.89. The business’s 50-day moving average is $156.77 and its 200-day moving average is $141.20. Novartis AG has a 1 year low of $97.71 and a 1 year high of $170.46.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.04. Novartis had a return on equity of 40.53% and a net margin of 25.65%.The business had revenue of $13.86 billion for the quarter, compared to the consensus estimate of $13.85 billion. During the same period in the prior year, the business earned $1.98 EPS. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Equities research analysts predict that Novartis AG will post 8.45 earnings per share for the current year.

Novartis Dividend Announcement

The company also recently declared an annual dividend, which was paid on Monday, March 16th. Investors of record on Wednesday, March 11th were paid a dividend of $4.773 per share. This represents a yield of 306.0%. The ex-dividend date of this dividend was Wednesday, March 11th. Novartis’s dividend payout ratio is 43.02%.

Wall Street Analyst Weigh In

Several research analysts have commented on NVS shares. Wall Street Zen downgraded Novartis from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. HSBC reaffirmed a “reduce” rating and set a $112.00 target price on shares of Novartis in a report on Wednesday, December 10th. Barclays raised Novartis from an “underweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Citigroup reaffirmed a “buy” rating on shares of Novartis in a report on Thursday, February 5th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Novartis in a report on Thursday, February 12th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Novartis presently has an average rating of “Hold” and an average target price of $141.20.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.